Deals
AstraZeneca to Buy Omthera Pharma for $323 Million
This article is for subscribers only.
AstraZeneca Plc agreed to pay about $323 million for Omthera Pharmaceuticals Inc., a U.S. developer of treatments for abnormal levels of fats in the bloodstream, as the U.K. company’s best-selling drug faces competition.
AstraZeneca will pay $12.70 a share for Omthera, or 88 percent more than the $6.77 closing price on May 24, it said today in a statement. Omthera shares doubled in New York.